This randomized phase III trial is studying different types of surgery to compare how well they work in treating patients with stage IA non-small cell lung cancer. Wedge resection or segmentectomy may be less invasive types of surgery than lobectomy for non-small cell lung cancer and may have fewer side effects and improve recovery. It is not yet known whether wedge resection or segmentectomy are more effective than lobectomy in treating stage IA non-small cell lung cancer.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT00499330.
PRIMARY OBJECTIVES:
I. To determine whether disease-free survival (DFS) after sublobar resection (segmentectomy or wedge) is non-inferior to that after lobectomy in patients with small peripheral (=< 2 cm) non-small cell lung cancer (NSCLC).
SECONDARY OBJECTIVES:
I. To determine whether overall survival (OS) (after sublobar resection) is non-inferior to that after lobectomy.
II. To determine the rates of loco-regional and systemic recurrence (exclusive of second primaries) after lobar and sublobar resection.
III. To determine the difference between the two arms of the study in pulmonary function as determined by expiratory flow rates measured at 6 months post-operatively.
IV. To explore the relationship between characteristics of the primary lung cancer, as revealed by pre-operative computed tomography (CT) and positron emission tomography (PET) imaging, and outcomes.
V. Determine the false-negative rate of preoperative PET scan for identification of involved hilar and mediastinal lymph nodes.
VI. Assess the utility of annual follow-up CT imaging after surgical resection of small stage IA NSCLC.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM I: Patients undergo lobectomy by open thoracotomy or video-assisted thoracoscopic surgery (VATS).
ARM II: Patients undergo a wedge resection or anatomical segmentectomy by open thoracotomy or VATS.
After completion of study treatment, patients are followed up every 6 months for 2 years and then annually for 5 years.
Lead OrganizationAlliance for Clinical Trials in Oncology
Principal InvestigatorNasser K. Altorki